Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ET B receptors. J. Appl. Physiol. 81(4): 1510-1515, 1996.-The pulmonary circulation plays an important role in the removal of circulating endothelin-1 (ET-1). Plasma ET-1 levels are increased in pulmonary hypertensive states of various etiologies (e.g., idiopathic, heart failure, and congenital anomalies) in proportion to the severity of pulmonary hypertension. It is possible that reduced pulmonary clearance of this peptide contributes to the hyperendothelinemia of those pathologies. The ET A and ET B receptors are abundant in lung tissues: on the vascular endothelium, the ET B receptor is predominant and may contribute to ET-1 extraction through receptor-mediated endocytosis. We designed experiments to determine and quantify the importance of the ET A and ET B receptors in the pulmonary extraction of circulating ET-1 in anesthetized dogs. The single-pass cumulative tracer ET-1 extraction by the lung was measured with the indicator-dilution technique before and 5 min after intrapulmonary injection of the specific ET A antagonist BQ-123 (n 5 5, 120-960 nmol) and the specific ET B antagonist BQ-788 (n 5 6, 1,000 nmol). The inhibitors had no significant effect on pulmonary and systemic hemodynamics. Mean cumulative pulmonary ET-1 extraction was not modified by BQ-123 [control (C): 36 6 4%, antagonist (A): 34 6 6%] but was completely abolished by BQ-788 (C: 34 6 6%, A: 0 6 2%, P , 0.001). The pulmonary rate constant (K) for ET-1 removal was also unaffected by BQ-123 (C: 0.050 6 0.0085 s 21 , A: 0.047 6 0.012 s 21 ) but significantly decreased and became close to zero after BQ-788 (C: 0.058 6 0.014 s 21 , A: 0.009 6 0.007 s 21 , P , 0.001). We conclude that the ET B receptor is completely and exclusively responsible for pulmonary ET-1 removal in vivo. Future studies are needed to show whether desensitization or downregulation of the ET B receptor may contribute to the increase in circulating ET-1 levels in conditions associated with pulmonary hypertension. This novel pulmonary endothelial cell function may play a protective role by modulating circulating ET-1 levels in the systemic circulation. endothelin receptors; pulmonary metabolism; BQ-123; BQ-788 THE PULMONARY CIRCULATION effectively produces, modifies, and inactivates numerous circulating substances but, more specifically, vasoactive amines and peptides. Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by vascular endothelial cells with a preferential abluminal secretion to effectively interact with the subjacent smooth muscle layer. ET-1 is nevertheless present in the circulation in small measurable amounts, and circulating ET-1 levels are increased up to fivefold in various pathological conditions (2, 15, 16) . The fate of circulating ET-1 is incompletely understood, but it is rapidly removed by the pulmonary circulation of various species, suggesting that the lungs are an important site for ET-1 clearance (1, 5, 14, 18). The lung contains ET A and ET B receptors: ET A receptors are particularly abundant in the blood vessels and bronchi, whereas the alveolar walls of the lung parenchyma are rich in ET B receptors (11). The ET B receptors are abundant on endothelial cells and possess equal affinity for the three isoforms of the endothelin family. Stimulation of the endothelial ET B causes vasodilation through the release of nitric oxide and prostacyclin (9, 17). It was recently shown that ET B receptor blockade reduces ET-1 removal by the lung, so the ET B receptor could also act as a clearance receptor for ET-1 in the pulmonary circulation (6). In cultured human endothelial cells, the specific ET B antagonist BQ-788 strongly inhibits labeled ET-1 binding to the cells and increases extracellular ET-1 levels, whereas the specific ET A antagonist BQ-123 only weakly inhibits ET-1 binding and does not modulate extracellular ET-1 levels (12). We designed experiments to better define the role and importance of the ET A and ET B receptors in circulating ET-1 clearance by the lungs. We measured the singlepass pulmonary removal of radiolabeled ET-1 in anesthetized dogs before and after intrapulmonary injections of single doses of ET A and ET B receptor antagonists.
THE PULMONARY CIRCULATION effectively produces, modifies, and inactivates numerous circulating substances but, more specifically, vasoactive amines and peptides. Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by vascular endothelial cells with a preferential abluminal secretion to effectively interact with the subjacent smooth muscle layer. ET-1 is nevertheless present in the circulation in small measurable amounts, and circulating ET-1 levels are increased up to fivefold in various pathological conditions (2, 15, 16) . The fate of circulating ET-1 is incompletely understood, but it is rapidly removed by the pulmonary circulation of various species, suggesting that the lungs are an important site for ET-1 clearance (1, 5, 14, 18) . The lung contains ET A and ET B receptors: ET A receptors are particularly abundant in the blood vessels and bronchi, whereas the alveolar walls of the lung parenchyma are rich in ET B receptors (11) . The ET B receptors are abundant on endothelial cells and possess equal affinity for the three isoforms of the endothelin family. Stimulation of the endothelial ET B causes vasodilation through the release of nitric oxide and prostacyclin (9, 17) . It was recently shown that ET B receptor blockade reduces ET-1 removal by the lung, so the ET B receptor could also act as a clearance receptor for ET-1 in the pulmonary circulation (6) . In cultured human endothelial cells, the specific ET B antagonist BQ-788 strongly inhibits labeled ET-1 binding to the cells and increases extracellular ET-1 levels, whereas the specific ET A antagonist BQ-123 only weakly inhibits ET-1 binding and does not modulate extracellular ET-1 levels (12) . We designed experiments to better define the role and importance of the ET A and ET B receptors in circulating ET-1 clearance by the lungs. We measured the singlepass pulmonary removal of radiolabeled ET-1 in anesthetized dogs before and after intrapulmonary injections of single doses of ET A and ET B receptor antagonists.
MATERIALS AND METHODS
Surgical instrumentation. Eleven healthy mongrel dogs (26 6 5.9 kg body wt) were consecutively studied. Anesthesia was induced with pentobarbital sodium (50 mg/kg), and the animals were intubated and mechanically ventilated using room air. Cutaneous electrocardiographic leads were installed, and a right arterial femoral catheter was inserted using the Seldinger technique for continuous blood pressure monitoring. The external right jugular vein was exposed, and a 7F multipurpose catheter was inserted and positioned in the pulmonary artery by use of fluoroscopic and pressuretracing guidance. The left carotid artery was then dissected, and a modified 7F pig-tail catheter was advanced and positioned 2 cm above the aortic valve. To prevent clotting of the catheters, 3,000 U of heparin were administered intravenously.
Single-pass pulmonary ET-1 clearance. Pulmonary removal of ET-1 was measured with the single-bolus dual-label indicator-dilution technique, as previously described (5) . The indicator-dilution curve was carried out by injection of a 2-ml bolus in the right ventricular outflow tract (just below the pulmonary valve) and simultaneous collection of subsequent fractions of blood from the root of the aorta with a Masterflex roller pump and a fraction collector. The injected bolus contained 4 µCi of 125 I-ET-1 (sp act 2,200 Ci/mmol), 1 ml of Evans blue dye-labeled albumin (5 mg/ml; this dye binds tightly with albumin and is utilized as a vascular tracer that does not leave the vascular space within a single transit time), bovine serum albumin (4 g/100 ml), and unlabeled red blood cells and saline to match the hematocrit of the dog.
An aliquot of blood from each of the collected fractions was assayed in a gamma counter to determine 125 I-ET-1 activity. The remaining blood was then centrifuged at 1,800 g for 10 min, and an aliquot of supernatant was assayed in a spectrophotometer for the determination of Evans blue dye absorbance (620-740 nm). Standards were prepared from the injection mixture and treated in an identical manner. The amount of tracer activity retained in the injection catheter was also determined and subtracted from the volume of the bolus to determine the exact quantity that was injected for each experiment. The fractional recovery of each tracer, for each fraction, could then be determined, and indicatordilution curves were constructed by plotting the fractional recovery as a function of time.
To provide a basis for comparison between the two indicators injected, the concentration of each was normalized in terms of the total injected; this is equivalent to defining the total amount of each material injected as 1 unit. The outflow fraction for each tracer is then defined as its outflow fractional recovery per milliliter of blood. Using this approach, we have shown that tracers that do not leave the vascular space of the lung perfectly superposed one onto the other. A permeating tracer, on the other hand, will separate from the vascular reference tracer. The recirculating portion of the indicator-dilution curve is removed by linear extrapolation of the semilogarithmic downslope after the classic method of Hamilton. Blood flow can then be calculated with the following relationship
where F b is the pulmonary blood flow and C(t) is the outflow fractional recovery vs. time curve for the Evans blue dyelabeled albumin. The integral in the denominator is consequently the area under the fractional recovery vs. time curve for the same tracer. The mean transit time for each tracer was calculated as
where t cath is the mean transit time through the catheters of the injection and collection system. Instantaneous tracer ET-1 extraction for any given fraction may be calculated from
where E(t) is the instantaneous tracer ET-1 extraction and C ET (t) and C Alb (t) are tracer endothelin and albumin outflow fractions per milliliter, respectively, at time t.
The cumulative tracer ET-1 extraction was calculated as
where the numerator and denominator represent the area under the fractional recovery curves for tracer ET-1 and tracer albumin, respectively. Using this methodology, we previously showed a mean cumulative tracer ET-1 extraction of 31 6 8% in the anesthetized dog (5) .
Effect of ET A and ET B receptor antagonists on pulmonary ET-1 clearance.
For each animal, an indicator-dilution curve was performed at baseline and 5 min after intrapulmonary injection of a single bolus dose of an ET A or ET B antagonist. The highly specific ET A antagonist BQ-123 was injected in doses ranging from 120 to 960 nmol (n 5 5). The effect of ET B blockade was verified by the injection of the highly specific ET B antagonist BQ-788 (n 5 6, 1,000 nmol). For each antagonist, one experiment was carried out with addition of the antagonist directly to the bolus injection mixture itself, rather than pretreatment of the animals by injection of the antagonists alone in the pulmonary artery; this manipulation was done to maximize the concentration of inhibitors at the level of the microcirculation at the time they may compete with labeled ET-1 in the removal process.
Statistical analysis. Group values are given as means 6 SD. A two-tailed paired t-test was used to assess differences between parameters after ET receptor antagonists.
RESULTS
All baseline hemodynamic parameters (heart rate, systemic and pulmonary pressures, and blood flow) were within normal limits for the three groups (Table  1 ). There was no significant effect of BQ-123 or BQ-788 intrapulmonary infusions on pulmonary or systemic hemodynamic parameters measured 5 min after infusion (Table 1) . Control arterial blood gases were also within normal range (for the 2 groups combined, pH 5 7.38 6 0.06, PO 2 5 105 6 10 Torr, PCO 2 5 37 6 8 Torr) and were unaffected by antagonist infusions.
A typical set of indicator-dilution studies is depicted in Fig. 1 . During control experiments, the tracer ET-1 recovery curve progressively separates from the albumin curve as ET-1 is being progressively extracted by the pulmonary microcirculation. Cumulative ET-1 extraction for the examples shown was 37 and 33% for the respective control experiments for BQ-123 and BQ-788. After BQ-123 infusion (Fig. 1B) there was no variation in the relationships between tracer ET-1 and albumin, with an unchanged cumulative extraction of 38%. However, after BQ-788 infusion, the tracer outflow profiles for ET-1 and albumin virtually superpose one Values are means 6 SD. Hemodynamic parameters were measured in control conditions (C) and 5 min after intrapulmonary infusion (I) of 2 different endothelin antagonists. Antagonists had no significant effects on systemic or pulmonary hemodynamics. SBP, systemic blood pressure; PAP, pulmonary arterial pressure. P is nonsignificant for infusion vs. control for all parameters.
onto the other, indicating that ET-1 pulmonary removal has been completely abolished by this antagonist (from 33 to 3%).
Data derived from indicator-dilution analysis are assembled in Table 2 . The mean pulmonary transit times for ET-1 and albumin were unaffected by the two antagonists. The specific ET A receptor antagonist BQ-123 did not affect mean cumulative pulmonary ET-1 clearance (from 36.4 6 4.2 to 34.0 6 6.4%, P 5 0.51). The specific ET B antagonist BQ-788, however, completely abolished pulmonary ET-1 removal (from 33.5 6 6.6 to 20.3 6 2.6%, P , 0.001).
Further analysis of the outflow profile relationships of the tracers helps characterize the ET-1 extraction process. Instantaneous ET-1 extraction increases linearly as a function of time over the whole of the primary dilution curve (before recirculation). A plot of the natural logarithm of the fractional recovery per milliliter of the vascular reference albumin over that of ET-1 as a function of time systematizes the relationship between the two tracers (Fig. 2) . Such a plot depicts a characteristic linear increase, as previously described (5), suggesting that the underlying capillary transit times are inhomogeneously distributed: capillaries with Fig. 1 . Typical set of dilution curves before (A) and after (B) intrapulmonary injection of specific endothelin receptor antagonists. Outflow profile for albumin (j) and tracer endothelin-1 (ET-1, r) is shown for each run. Mean percent ET-1 extraction by pulmonary circulation, corresponding to difference between areas of extrapolated albumin and tracer ET-1 curves, is indicated. ET-1 extraction was not modified by antagonist BQ-123, whereas it was completely abolished by specific ET B antagonist BQ-788. Curves for BQ-123 and BQ-788 correspond to expts 4 and 11, respectively (see Table 2 ). progressively longer transit times contribute to ET-1 extraction, explaining the linear increase in extraction with time. If a significant portion of the extracted ET-1 returned to the circulation, one would expect a flattening or decrease, later in time, of the log ratio curve. Such behavior is evident for a tracer like serotonin, which partly backdiffuses into the circulation after pulmonary extraction. Here, the constant linear increase in the log ratio therefore suggests that, over a single passage, the extracted endothelin is retained within endothelial cells and does not return to the circulation. The foregoing therefore suggests that the outflow relationship for tracer ET-1 can be described by C ET (t) 5 C Alb (t)e 2K(t 2 to) (5) where K is an uptake rate constant and t o is a common large vessel transit time. With the assumption of no variations in large vessel transit time (3), K can be estimated by computing the slope of the log ratio plots (Fig. 2) . In the absence of correction for large vessels and catheter distortion, the value will be a minimum; it will be slightly smaller than the actual value. If formulated in terms of ordinary capillary modeling, K corresponds to PS c /V c , the product of the vascular permeability (P) and the surface-to-volume ratio for the pulmonary capillaries (S c /V c ). In the present set of experiments, where pulmonary blood flow and pressures remained constant, we may assume that S c /V c also remains constant and that K becomes an index of capillary permeability to circulating ET-1.
An example of a log ratio plot at baseline and after BQ-788 infusion is shown in Fig. 2 (expt 10) , and the individual values for all experiments are assembled in Table 2 . Control values for K are similar to the previously reported value of 0.056 6 0.016 s 21 (5) and do not significantly vary after BQ-123 (P 5 0.73). Because the ET B antagonist BQ-788 completely abolished ET-1 extraction, K decreased from 0.058 6 0.009 to 0.009 6 0.007 s 21 (P , 0.001) after that pharmacological intervention.
The specific ET B antagonist BQ-788 completely abolished ET-1 removal by the lung after a single injection of 1,000 nmol for all animals studied. The ET A antagonist BQ-123 could not modify ET-1 extraction in equivalent doses. To greatly increase inhibitor concentration at the microcirculatory level, one experiment was performed with addition of ,1,000 nmol of the inhibitors to the indicator-dilution injection mixture itself, rather than pretreatment of the animals by intrapulmonary injection of the inhibitors 5 min before the dilution study. Because the quantity of tracer ET-1 simultaneously injected was ,2 pmol, this creates an antagonist-to-agonist ratio of 5 3 10 5 :1. Addition of the inhibitors to the bolus itself did not modify ET-1 extraction for BQ-123, whereas it still completely abolished extraction with BQ-788, as expected ( Table 2) .
DISCUSSION
We have shown that in vivo pulmonary removal of circulating ET-1 is completely and exclusively mediated by the ET B receptors. The ET A receptor is preponderant in the vascular smooth muscle, whereas the ET B receptor is more abundant in the vascular endothelium (9) . Stimulation of the ET B receptor causes mixed responses depending on the species and vascular bed studied. In the piglet lung, an initial dose-dependent dilatation is followed by a dose-dependent vasoconstriction (13) . A nomenclature is suggested to distinguish between ET B1 (dilator response) and ET B2 (constrictor response) receptors. Another potentially important role for the ET B receptor was recently unveiled when Fukuroda et al. (6) demonstrated that the ET B receptor contributes to pulmonary removal of circulating ET-1 in rat lungs. Using in vivo and isolated lung preparations, they demonstrated that the specific ET B antagonist BQ-788 significantly decreased ET-1 removal by the pulmonary circulation whereas the ET A antagonist BQ-123 had no significant effect. The major difference between the experiments of Fukuroda et al. and the present study is that BQ-788 incompletely prevented ET-1 removal by the lung, so other mechanisms for ET-1 removal could not be excluded.
The indicator-dilution technique is the most accurate method to study microcirculatory exchanges in vivo. Using this technique, we previously demonstrated that the canine pulmonary circulation extracts 31 6 8% of circulating ET-1 during a single pulmonary transit time with a simultaneous equal release of ET-1 into the circulation, explaining the absence of arteriovenous difference in immunoreactive ET-1 levels across the pulmonary circulation (5) . In the present study we not only confirm the role of the ET B receptor in pulmonary removal of circulating ET-1 but, more specifically, establish its exclusivity, because ET-1 removal was completely abolished by the specific ET B receptor antagonist BQ-788 (from 33.5 6 6.6 to 20.3 6 2.6%). The specific ET A antagonist BQ-123 could not reduce ET-1 pulmonary removal. To ensure high enough concentration of BQ-123 in the microcirculation, we added the inhibitors directly to the indicator-dilution mixture to create an inhibitor-to-agonist ratio of ,1 3 10 5 :1. This Fig. 2 . Natural log ratio plot of fractional recovery per ml of tracer albumin over tracer ET-1 as a function of time (expt 10) before (r) and after (j) BQ-788 infusion. At baseline, log ratio increases linearly, and a rate constant (K) characterizing ET-1 extraction can be estimated from slope of this relationship. ET-1 removal by lung is unidirectional without significant return of tracer to circulation during a single pulmonary transit time. After BQ-788, log ratio becomes a flat line and K is close to zero.
procedure did not modify the pulmonary ET-1 removal patterns: only BQ-788 completely abolished pulmonary ET-1 removal.
Although ET-1 removal was totally abolished, we did not detect a significant hemodynamic effect after BQ-788 infusion. We, however, only measured pressures 5 min after inhibitor injection, and this does not exclude later hemodynamic alterations. The clearance role of the ET B receptor may have important pathological and therapeutic implications. Desensitization or downregulation of this receptor may contribute to increased ET-1 levels in various disorders. Rats with monocrotaline pulmonary hypertension have decreased expression of ET B receptors (19) . Because most pathologies associated with pulmonary hypertension have a hyperendothelinemia that is proportional to the severity of pulmonary hypertension (2, 10, 16, 20) , it is possible that altered ET B function and/or expression contributes to the process by reducing pulmonary ET-1 clearance. Specific ET B antagonists and nonspecific ET A and ET B antagonists can increase circulating endothelin levels: in normal and hypertensive dogs, the nonspecific ET A and ET B antagonist bosentan causes a 30-fold increase in ET-1 levels (4). In humans with heart failure, a single dose of bosentan doubles the already high circulating ET-1 levels (7). In conscious rats, ET A antagonists (BQ-123 and FR-139317) do not affect circulating ET-1 levels, whereas the nonspecific ET A and ET B blocker Ro-462005 increased circulating ET-1 levels by 200% (8) . Studies done on cultured human endothelial cells confirm the predominance of the ET B receptor on the endothelium and its unique role in the modulation of extracellular ET-1 levels (12). Our data confirm this unique role of the ET B receptor in vivo. Like most pulmonary metabolic functions, the ET B receptor may have a protective role by modulating the systemic levels of a potent circulating vasoconstrictor. This new important role of the ET B receptor must be considered when experiments with endothelin receptor antagonists are designed and introduces the possibility of a ''rebound phenomenon'' secondary to the increased ET-1 levels after ET B receptor blockade.
The mechanism by which ET B receptors mediate ET-1 clearance remains to be determined but could be through receptor-mediated endocytosis. The fate of ET B receptor-bound ET-1 also remains unknown. Endothelial ET B receptors may clear circulating ET-1 and mediate its inactivation through later intracellular degradation or act as a transendothelial transporter that delivers ET-1 at the abluminal surface of the endothelium.
Pulmonary clearance of circulating ET-1 by the endothelial ET B receptor represents a novel endothelial cell function. The pulmonary circulation modifies and inactivates numerous vasoactive amines and peptides and may modulate the systemic levels of these substances. There is normally no net arteriovenous difference in circulating ET-1 levels across the lung (5, 16) ; the lung consequently produces an amount of ET-1 equal to the amount that has been extracted (5) . Conditions associated with pulmonary endothelial cell dysfunction or pharmacological blockade of the ET B receptor may consequently alter this physiological balance and contribute to an increase in ET-1 levels.
